All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings.
These reports are called 13F reports. However, the filings are required
the following quarter
from the reporting period,
which means that by the time the filing is made (and we see them), the information could be five months old.
For funds
with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover,
the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions
are identified in the table. However, they are not required to report short positions.
Click the link icon to see the full transaction history.
Upgrade
to unlock premium data and export to Excel 
.
| Security |
Imputed
Share Price |
Prev
Shares |
Current
Shares |
Change
(Percent) |
Prev Value
(USD x1000) |
Current Value
(USD x1000) |
Change
(Percent) |
|---|
| KDNY / Chinook Therapeutics Inc
|
|
|
|
|
|
|
|
| MRUS / Merus N.V.
|
|
|
|
|
|
|
|
| NXTC / NextCure, Inc.
|
|
|
|
|
|
|
|
| AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| XCUR / Exicure, Inc.
|
|
|
|
|
|
|
|
| VCEL / Vericel Corporation
|
|
|
|
|
|
|
|
| SYRS / Syros Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| ASMB / Assembly Biosciences, Inc. Call
|
|
|
|
|
|
|
|
| RGLS / Regulus Therapeutics Inc.
|
|
|
|
|
|
|
|
| IGMS / IGM Biosciences, Inc.
|
|
|
|
|
|
|
|
| FGEN / FibroGen, Inc. Call
|
|
|
|
|
|
|
|
| MORF / Morphic Holding, Inc.
|
|
|
|
|
|
|
|
| US74140Y1010 / Prevail Therapeutics Inc.
|
|
|
|
|
|
|
|
| HARP / Harpoon Therapeutics, Inc.
|
|
|
|
|
|
|
|
| ARQL / ArQule, Inc.
|
|
|
|
|
|
|
|
| US16706W1027 / Chiasma Inc
|
|
|
|
|
|
|
|
| KZR / Kezar Life Sciences, Inc.
|
|
|
|
|
|
|
|
| RYTM / Rhythm Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| PRTA / Prothena Corporation plc
|
|
|
|
|
|
|
|
| CRTX / Cortexyme Inc
|
|
|
|
|
|
|
|
| ONCE / Spark Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RARE / Ultragenyx Pharmaceutical Inc.
|
|
|
|
|
|
|
|
| IRWD / Ironwood Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| FGEN / FibroGen, Inc.
|
|
|
|
|
|
|
|
| GMDA / Gamida Cell Ltd.
|
|
|
|
|
|
|
|
| EIGR / Eiger BioPharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| LRMR / Larimar Therapeutics, Inc.
|
|
|
|
|
|
|
|
| BCEL / Atreca, Inc.
|
|
|
|
|
|
|
|
| TCRR / Tcr2 Therapeutics Inc
|
|
|
|
|
|
|
|
| DRNA / Dicerna Pharmaceuticals Inc
|
|
|
|
|
|
|
|
| RCUS / Arcus Biosciences, Inc.
|
|
|
|
|
|
|
|
| ASMB / Assembly Biosciences, Inc.
|
|
|
|
|
|
|
|
| NLTX / Neoleukin Therapeutics, Inc.
|
|
|
|
|
|
|
|
| RUBY / Rubius Therapeutics, Inc.
|
|
|
|
|
|
|
|
| UBX / Unity Biotechnology, Inc.
|
|
|
|
|
|
|
|
| NGM / NGM Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
|
| GOSS / Gossamer Bio, Inc. Call
|
|
|
|
|
|
|
|
| GOSS / Gossamer Bio, Inc.
|
|
|
|
|
|
|
|
| CRIS / Curis, Inc.
|
|
|
|
|
|
|
|
| CYCN / Cyclerion Therapeutics, Inc.
|
|
|
|
|
|
|
|
| SLDB / Solid Biosciences Inc.
|
|
|
|
|
|
|
|
| SURF / Surface Oncology Inc
|
|
|
|
|
|
|
|
| CRSP / CRISPR Therapeutics AG
|
|
|
|
|
|
|
|
| XNCR / Xencor, Inc.
|
|
|
|
|
|
|
|
| ARGX / argenx SE - Depositary Receipt (Common Stock)
|
|
|
|
|
|
|
|
| SRPT / Sarepta Therapeutics, Inc.
|
|
|
|
|
|
|
|
| MRTX / Mirati Therapeutics, Inc.
|
|
|
|
|
|
|
|
| MRSN / Mersana Therapeutics, Inc.
|
|
|
|
|
|
|
|
| KURA / Kura Oncology, Inc.
|
|
|
|
|
|
|
|
